Regular long acting v short acting inhaled β2 agonists in adults and children with chronic asthma
| Outcomes at 2–24 weeks (number of studies) | Weighted mean difference (95% CI) |
|---|---|
| Morning peak expiratory flow (l/min) (n=8) | 33 (25 to 41) |
| Evening peak expiratory flow (l/min) (n=8) | 26 (18 to 33) |
| Forced expiratory volume in 1 second (l) (n=8) | 0.23 (0.14 to 0.31) |
| Daytime asthma symptom score (n=3) | −0.15 (−0.23 to −0.06) |
| Night time asthma symptom score (n=3) | −0.21 (−0.31 to −0.10) |
| Percentage of days without symptoms (n=2) | 10 (2 to 19) |
| Percentage of nights without symptoms (n=3) | 12 (8 to 16) |
| Daytime use of rescue bronchodilators (puffs/24 h) (n=4) | −0.33 (−0.50 to −0.16) |
| Night time use of rescue bronchodilators (puffs/24 h) (n=4) | −0.31 (−0.43 to −0.19) |
